الفهرس 
Introduction
Aim of the workOnly 14 pages are availabe for public view
 |  | from | 84 |  |  |
| | | from | 84 | | |
Abstract
Obesity is a leading preventable cause of death worldwide, with increasing rates in adults and children. Obesity is more common in women than men. In 2013, the American Medical Association classified obesity as a disease. The most effective treatment for obesity and its associated comorbidities is bariatric surgery in its various forms. Bariatric surgery has become a safe, effective and proven therapy. Surgical treatment is medically necessary because it is the only proven method of achieving long-term weight control for the morbidly obese.
In 2009, the American Society for Metabolic and Bariatric Surgery (ASMBS) issued a position statement recommending LSG as an approved primary bariatric procedure. At present LSG is the second most performed bariatric procedure after Roux-en-Y gastric bypass (RYGB), and it has the fastest increment rate in the last decade.
A prospective study plus a retrospective analysis of our prospectively maintained database is carried out to identify all patients with BMI ≥ 40 kg/m2 or BMI ≥35 kg/m2 with co-morbid conditions who underwent LSG. Data regarding weight loss during first 12 months after LSG is assessed.